Study Finds No Benefit in Modulating Antiplatelet Therapy After Complex Stenting Procedures

A recent study shows that tailoring antiplatelet therapy post-complex coronary stenting does not improve outcomes and may increase bleeding risks. Standard 12-month DAPT remains the recommended approach.
Recent research presented at ESC Congress 2025 has shown that adjusting the intensity of antiplatelet therapy—either through early escalation or late de-escalation—does not improve outcomes in patients who have undergone complex coronary stenting procedures. The study, known as the TAILORED-CHIP trial, involved 2,018 high-risk patients across South Korea, comparing tailored antiplatelet strategies to standard therapy.
Typically, dual antiplatelet therapy (DAPT), consisting of aspirin plus a P2Y12 inhibitor like clopidogrel, is prescribed after percutaneous coronary intervention (PCI) to prevent ischemic events such as heart attacks. The rationale for the trial was that high-risk patients might benefit from a customized approach—using stronger inhibition early on to prevent ischemia, then weakening the regimen later to reduce bleeding risk.
In the trial, one group received a tailored approach: low-dose ticagrelor combined with aspirin for six months, followed by monotherapy with clopidogrel for another six months. The control group received the standard 12 months of clopidogrel plus aspirin. Results revealed no significant difference in the primary composite outcome of adverse events, which included death, heart attack, stroke, stent thrombosis, unplanned revascularization, or major bleeding, between the two groups after 12 months.
Interestingly, the tailored therapy group experienced a higher rate of clinically relevant bleeding (7.2%) compared to the standard therapy group (4.8%), while major bleeding rates were similar. Additionally, there was no notable reduction in ischemic events with the tailored approach.
Professor Duk-Woo Park from Seoul’s Asan Medical Center concluded that this study challenges the assumption that more aggressive or tailored antiplatelet strategies offer additional benefits in complex PCI patients. The findings support the continued use of standard 12-month DAPT for high-risk patients, as personalized approaches did not demonstrate clear net clinical advantages but did increase bleeding complications.
Overall, these results inform clinical decision-making, emphasizing that a more intensive or variable antiplatelet regimen does not necessarily translate to better outcomes in complex stenting cases.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Revolutionizing Critical Care: Immune Cell Signatures as Guides for Treatment
Innovative blood tests analyzing immune cell gene signatures are set to revolutionize diagnosis and personalized treatment in critical care, enhancing outcomes for severely ill patients.
Study Shows Cost-Effective Benefits of Intensive Blood Pressure Targets
Research shows that intensive blood pressure control below 120 mm Hg is a cost-effective strategy to reduce cardiovascular events, despite potential risks and higher healthcare costs. Learn about the latest findings on blood pressure management.
Innovative Approaches Urged to Integrate Dentistry into Primary Care
Experts highlight the urgent need to embed dental health within primary care to improve disease prevention, manage chronic illnesses, and promote health equity through interprofessional collaboration and policy reforms.
How a Defective Brain Transport Protein Can Lead to Severe Epilepsy
Researchers have uncovered how mutations in the SLC13A5 transporter impair citrate uptake in neurons, leading to severe epilepsy and developmental delays. This study advances understanding of genetic causes of neurological disorders and paves the way for targeted treatments.